Study Features and Response Compliance in Ecological Momentary Assessment Research in Borderline Personality Disorder: Systematic Review and Meta-analysis.

borderline personality disorder compliance ecological momentary assessment e–mental health mobile phone study design features

Journal

Journal of medical Internet research
ISSN: 1438-8871
Titre abrégé: J Med Internet Res
Pays: Canada
ID NLM: 100959882

Informations de publication

Date de publication:
15 03 2023
Historique:
received: 06 12 2022
accepted: 31 01 2023
revised: 17 01 2023
entrez: 15 3 2023
pubmed: 16 3 2023
medline: 21 3 2023
Statut: epublish

Résumé

Borderline personality disorder (BPD) is characterized by frequent and intense moment-to-moment changes in affect, behavior, identity, and interpersonal relationships, which typically result in significant and negative deterioration of the person's overall functioning and well-being. Measuring and characterizing the rapidly changing patterns of instability in BPD dysfunction as they occur in a person's daily life can be challenging. Ecological momentary assessment (EMA) is a method that can capture highly dynamic processes in psychopathology research and, thus, is well suited to study intense variability patterns across areas of dysfunction in BPD. EMA studies are characterized by frequent repeated assessments that are delivered to participants in real-life, real-time settings using handheld devices capable of registering responses to short self-report questions in daily life. Compliance in EMA research is defined as the proportion of prompts answered by the participant, considering all planned prompts sent. Low compliance with prompt schedules can compromise the relative advantages of using this method. Despite the growing EMA literature on BPD in recent years, findings regarding study design features that affect compliance with EMA protocols have not been compiled, aggregated, and estimated. This systematic meta-analytic review aimed to investigate the relationship between study design features and participant compliance in EMA research of BPD. A systematic review was conducted on November 12, 2021, following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) and MOOSE (Meta-analyses of Observational Studies in Epidemiology) guidelines to search for articles featuring EMA studies of BPD that reported compliance rates and included sufficient data to extract relevant design features. For studies with complete data, random-effect models were used to estimate the overall compliance rate and explore its association with design features. In total, 28 peer-reviewed EMA studies comprising 2052 participants were included in the study. Design features (sampling strategy, average prompting frequency, number of items, response window, sampling device, financial incentive, and dropout rate) showed a large variability across studies, and many studies did not report design features. The meta-analytic synthesis was restricted to 64% (18/28) of articles and revealed a pooled compliance rate of 79% across studies. We did not find any significant relationship between design features and compliance rates. Our results show wide variability in the design and reporting of EMA studies assessing BPD. Compliance rates appear to be stable across varying setups, and it is likely that standard design features are not directly responsible for improving or diminishing compliance. We discuss possible nonspecific factors of study design that may have an impact on compliance. Given the promise of EMA research in BPD, we also discuss the importance of unifying standards for EMA reporting so that data stemming from this rich literature can be aggregated and interpreted jointly.

Sections du résumé

BACKGROUND
Borderline personality disorder (BPD) is characterized by frequent and intense moment-to-moment changes in affect, behavior, identity, and interpersonal relationships, which typically result in significant and negative deterioration of the person's overall functioning and well-being. Measuring and characterizing the rapidly changing patterns of instability in BPD dysfunction as they occur in a person's daily life can be challenging. Ecological momentary assessment (EMA) is a method that can capture highly dynamic processes in psychopathology research and, thus, is well suited to study intense variability patterns across areas of dysfunction in BPD. EMA studies are characterized by frequent repeated assessments that are delivered to participants in real-life, real-time settings using handheld devices capable of registering responses to short self-report questions in daily life. Compliance in EMA research is defined as the proportion of prompts answered by the participant, considering all planned prompts sent. Low compliance with prompt schedules can compromise the relative advantages of using this method. Despite the growing EMA literature on BPD in recent years, findings regarding study design features that affect compliance with EMA protocols have not been compiled, aggregated, and estimated.
OBJECTIVE
This systematic meta-analytic review aimed to investigate the relationship between study design features and participant compliance in EMA research of BPD.
METHODS
A systematic review was conducted on November 12, 2021, following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) and MOOSE (Meta-analyses of Observational Studies in Epidemiology) guidelines to search for articles featuring EMA studies of BPD that reported compliance rates and included sufficient data to extract relevant design features. For studies with complete data, random-effect models were used to estimate the overall compliance rate and explore its association with design features.
RESULTS
In total, 28 peer-reviewed EMA studies comprising 2052 participants were included in the study. Design features (sampling strategy, average prompting frequency, number of items, response window, sampling device, financial incentive, and dropout rate) showed a large variability across studies, and many studies did not report design features. The meta-analytic synthesis was restricted to 64% (18/28) of articles and revealed a pooled compliance rate of 79% across studies. We did not find any significant relationship between design features and compliance rates.
CONCLUSIONS
Our results show wide variability in the design and reporting of EMA studies assessing BPD. Compliance rates appear to be stable across varying setups, and it is likely that standard design features are not directly responsible for improving or diminishing compliance. We discuss possible nonspecific factors of study design that may have an impact on compliance. Given the promise of EMA research in BPD, we also discuss the importance of unifying standards for EMA reporting so that data stemming from this rich literature can be aggregated and interpreted jointly.

Identifiants

pubmed: 36920466
pii: v25i1e44853
doi: 10.2196/44853
pmc: PMC10131785
doi:

Types de publication

Meta-Analysis Systematic Review Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e44853

Informations de copyright

©Antonella Davanzo, Delfine d´Huart, Süheyla Seker, Markus Moessner, Ronan Zimmermann, Klaus Schmeck, Alex Behn. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 15.03.2023.

Références

Personal Disord. 2016 Jan;7(1):50-60
pubmed: 26098377
Eur Neuropsychopharmacol. 2020 Sep;38:98-109
pubmed: 32703662
J Med Internet Res. 2016 Jun 21;18(6):e151
pubmed: 27328833
Stat Med. 2002 Jun 15;21(11):1559-73
pubmed: 12111920
J Affect Disord. 2013 Jul;149(1-3):1-13
pubmed: 23528438
Personal Disord. 2017 Oct;8(4):357-365
pubmed: 27505188
J Pers Assess. 2010 Nov;92(6):490-500
pubmed: 20954051
J Nerv Ment Dis. 2006 Oct;194(10):774-9
pubmed: 17041290
J Abnorm Psychol. 2017 May;126(4):429-440
pubmed: 28383936
Clin Psychol Sci. 2016 Sep;4(5):775-792
pubmed: 28042520
Nat Rev Dis Primers. 2018 May 24;4:18029
pubmed: 29795363
Borderline Personal Disord Emot Dysregul. 2017 May 21;4:8
pubmed: 28533905
Drug Alcohol Depend. 2021 Nov 1;228:109021
pubmed: 34508960
J Abnorm Psychol. 2008 Aug;117(3):647-61
pubmed: 18729616
Personal Disord. 2014 Oct;5(4):380-9
pubmed: 25314228
Psychol Addict Behav. 2020 Nov;34(7):745-755
pubmed: 32324000
Borderline Personal Disord Emot Dysregul. 2022 Apr 1;9(1):12
pubmed: 35361271
J Pers Disord. 2018 Jan;32(Suppl):36-57
pubmed: 29388895
Personal Disord. 2021 Jan;12(1):39-50
pubmed: 32297768
J Behav Ther Exp Psychiatry. 2013 Sep;44(3):279-84
pubmed: 23388468
Psychol Assess. 2009 Sep;21(3):425-36
pubmed: 19719353
Personal Disord. 2020 Jan;11(1):46-53
pubmed: 31670544
J Abnorm Psychol. 2011 Aug;120(3):681-90
pubmed: 21500875
J Psychiatr Pract. 2019 Jan;25(1):46-53
pubmed: 30633732
J Pers Disord. 2016 Feb;30(1):52-70
pubmed: 25710731
Psychol Addict Behav. 2020 Sep;34(6):650-659
pubmed: 32271056
J Pers Disord. 2014 Aug;28(4):555-76
pubmed: 22984853
J Psychother Integr. 2017;27(4):425-438
pubmed: 29527105
J Pers Disord. 2021 Mar;35(Suppl A):83-113
pubmed: 33107806
Br J Psychiatry. 2015 Oct;207(4):339-45
pubmed: 26159601
J Affect Disord. 2016 Nov 15;205:225-233
pubmed: 27449555
Assessment. 2023 Apr;30(3):825-846
pubmed: 35016567
Psychiatr Q. 2021 Sep;92(3):1035-1054
pubmed: 33475912
Affect Sci. 2020 Sep;1(3):117-127
pubmed: 33718882
Personal Disord. 2020 Mar;11(2):131-140
pubmed: 31621364
Psychiatr Clin North Am. 2018 Dec;41(4):561-573
pubmed: 30447724
Neuroimage Clin. 2019;24:102032
pubmed: 31795041
BMJ Open. 2021 Jul 30;11(7):e049154
pubmed: 34330860
Prev Med. 2007 Oct;45(4):247-51
pubmed: 17950122
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
Behav Ther. 2013 Sep;44(3):529-40
pubmed: 23768678
Eur Child Adolesc Psychiatry. 2021 Aug;30(8):1299-1308
pubmed: 32862250
Lancet. 2021 Oct 23;398(10310):1528-1540
pubmed: 34688371
Psychol Assess. 2019 Feb;31(2):226-235
pubmed: 30394762
J Pers Disord. 2016 Dec;30(6):776-795
pubmed: 26623534
J Abnorm Psychol. 2015 Feb;124(1):186-98
pubmed: 25603359
Assessment. 2016 Aug;23(4):484-495
pubmed: 27317561
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
Annu Rev Clin Psychol. 2013;9:151-76
pubmed: 23157450
World Psychiatry. 2018 Jun;17(2):123-132
pubmed: 29856567
J Abnorm Psychol. 2017 Nov;126(8):1057-1065
pubmed: 29154566
Psychol Assess. 2009 Dec;21(4):463-75
pubmed: 19947781
Acta Psychiatr Scand. 2008 Feb;117(2):139-47
pubmed: 18028248
J Pers Disord. 2021 Mar;35(Suppl A):162-171
pubmed: 33650892
J Abnorm Psychol. 2020 Jan;129(1):56-63
pubmed: 31868388
J Abnorm Psychol. 2012 Aug;121(3):668-79
pubmed: 22686872
J Psychopathol Behav Assess. 2020 Dec;42(4):702-713
pubmed: 33776200
Res Synth Methods. 2017 Mar;8(1):5-18
pubmed: 28058794
Psychiatry. 2019 Summer;82(2):173-178
pubmed: 31013205
J Pers Disord. 2007 Feb;21(1):72-86
pubmed: 17373891
J Med Internet Res. 2019 Dec 6;21(12):e14475
pubmed: 31808748
Annu Rev Clin Psychol. 2008;4:1-32
pubmed: 18509902
Ann Behav Med. 2002 Summer;24(3):236-43
pubmed: 12173681
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120

Auteurs

Antonella Davanzo (A)

Escuela de Psicología, Pontificia Universidad Católica de Chile, Instituto Milenio para la Investigación en Depresión y Personalidad, Santiago, Chile.

Delfine D Huart (D)

Department of Child and Adolescent Psychiatry Research, University Psychiatric Clinics, University of Basel, Basel, Switzerland.

Süheyla Seker (S)

Department of Child and Adolescent Psychiatry Research, University Psychiatric Clinics, University of Basel, Basel, Switzerland.

Markus Moessner (M)

University Hospital Heidelberg, Center for Psychotherapy Research, Heidelberg, Germany.

Ronan Zimmermann (R)

Department of Child and Adolescent Psychiatry Research, University Psychiatric Clinics, University of Basel, Basel, Switzerland.

Klaus Schmeck (K)

Department of Child and Adolescent Psychiatry Research, University Psychiatric Clinics, University of Basel, Basel, Switzerland.

Alex Behn (A)

Escuela de Psicología, Pontificia Universidad Católica de Chile, Instituto Milenio para la Investigación en Depresión y Personalidad, Santiago, Chile.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH